JP2004508065A - ＣＤ１１ｂ発現細胞に対する分子送達用ベクター - Google Patents

ＣＤ１１ｂ発現細胞に対する分子送達用ベクター Download PDF

Info

Publication number
JP2004508065A
JP2004508065A JP2002526418A JP2002526418A JP2004508065A JP 2004508065 A JP2004508065 A JP 2004508065A JP 2002526418 A JP2002526418 A JP 2002526418A JP 2002526418 A JP2002526418 A JP 2002526418A JP 2004508065 A JP2004508065 A JP 2004508065A
Authority
JP
Japan
Prior art keywords
adenyl cyclase
cd11b
cells
molecule
cyaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002526418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508065A5 (enExample
Inventor
レクレール，クロード
ゲルモンプレ，ピエール
ラダン，ダニエル
ギソ，ニコル
クレ，ナディア
ボシュ，セシル
ファヨル，カトリーヌ
エル−アザミ　エル−イドリッシ，モハメド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2004508065A publication Critical patent/JP2004508065A/ja
Publication of JP2004508065A5 publication Critical patent/JP2004508065A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002526418A 2000-09-15 2001-09-14 ＣＤ１１ｂ発現細胞に対する分子送達用ベクター Pending JP2004508065A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402562A EP1188446B1 (en) 2000-09-15 2000-09-15 Proteinaceous vectors for molecule delivery to CD11b expressing cells
PCT/EP2001/011315 WO2002022169A2 (en) 2000-09-15 2001-09-14 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS

Publications (2)

Publication Number Publication Date
JP2004508065A true JP2004508065A (ja) 2004-03-18
JP2004508065A5 JP2004508065A5 (enExample) 2011-12-01

Family

ID=8173866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526418A Pending JP2004508065A (ja) 2000-09-15 2001-09-14 ＣＤ１１ｂ発現細胞に対する分子送達用ベクター

Country Status (16)

Country Link
US (4) US20040001867A1 (enExample)
EP (2) EP1188446B1 (enExample)
JP (1) JP2004508065A (enExample)
KR (2) KR100879151B1 (enExample)
AT (2) ATE438409T1 (enExample)
AU (2) AU9385501A (enExample)
BR (1) BR0113915A (enExample)
CA (1) CA2422603A1 (enExample)
CZ (1) CZ2003726A3 (enExample)
DE (1) DE60042687D1 (enExample)
ES (1) ES2331348T3 (enExample)
HU (1) HUP0303126A3 (enExample)
PL (1) PL208864B1 (enExample)
PT (1) PT1188446E (enExample)
RU (1) RU2312143C2 (enExample)
WO (1) WO2002022169A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524270A (ja) * 2012-07-23 2015-08-24 ゲントイセル 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP2008500271A (ja) * 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
ES2337694T3 (es) * 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
RU2517719C2 (ru) * 2008-05-29 2014-05-27 Трансжене Са Биомаркер для отбора пациентов и соответствующие способы
PL2233569T3 (pl) 2009-03-23 2015-02-27 Pasteur Institut Zmutowane polipeptydy cyaa i pochodne polipeptydu odpowiednie do dostarczania cząsteczek immunogennych do komórki
CN102439146A (zh) * 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
WO2019177669A1 (en) * 2017-11-03 2019-09-19 Mackay Memorial Hospital Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597605B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Nouveau materiau pour chromatographie d'affinite et son application a la separation et a la purification des antigenes proteiques des bacteries du genre bordetella
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US5182211A (en) 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
US5312902A (en) 1988-06-09 1994-05-17 Institut Pasteur Dimer of the precursor of HIV-2 envelope glycoprotein
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2638169B1 (fr) 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
NO175188C (no) 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
EP1715047A3 (en) * 1992-04-21 2008-08-27 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
EP0831817B1 (en) * 1995-06-07 2001-03-14 Joel K. Swadesh Antigen-processing cell-targeted conjugates comprising a polyamino acid backbone and a non-steroidal anti-inflammatory agent
WO1997035882A1 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100773109B1 (ko) * 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
WO2001029220A2 (en) 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP2008500271A (ja) 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
ES2337694T3 (es) 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
US20070026022A1 (en) 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US8017132B2 (en) * 2009-03-23 2011-09-13 Institut Pasteur Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524270A (ja) * 2012-07-23 2015-08-24 ゲントイセル 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
JP2019013229A (ja) * 2012-07-23 2019-01-31 ゲントイセル 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用

Also Published As

Publication number Publication date
HUP0303126A2 (hu) 2003-12-29
AU9385501A (en) 2002-03-26
PT1188446E (pt) 2009-11-10
WO2002022169A3 (en) 2002-11-21
PL365743A1 (en) 2005-01-10
US20040001867A1 (en) 2004-01-01
DE60042687D1 (de) 2009-09-17
US10004794B2 (en) 2018-06-26
WO2002022169A2 (en) 2002-03-21
US9370564B2 (en) 2016-06-21
EP1317282B1 (en) 2011-08-03
EP1188446A1 (en) 2002-03-20
KR100953364B1 (ko) 2010-04-20
ES2331348T3 (es) 2009-12-30
RU2312143C2 (ru) 2007-12-10
US20120214206A1 (en) 2012-08-23
HUP0303126A3 (en) 2004-10-28
KR20080059684A (ko) 2008-06-30
CA2422603A1 (en) 2002-03-21
US20050238637A1 (en) 2005-10-27
BR0113915A (pt) 2003-07-01
AU2001293855B2 (en) 2007-04-26
EP1317282A2 (en) 2003-06-11
EP1188446B1 (en) 2009-08-05
PL208864B1 (pl) 2011-06-30
HK1057989A1 (en) 2004-04-30
ATE518880T1 (de) 2011-08-15
CZ2003726A3 (cs) 2003-09-17
ATE438409T1 (de) 2009-08-15
KR20030055265A (ko) 2003-07-02
KR100879151B1 (ko) 2009-01-19
US20160375119A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
US10004794B2 (en) Vectors for molecule delivery to CD11b expressing cells
Agren et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
Tao et al. Induction of IL-4-producing CD4+ T cells by antigenic peptides altered for TCR binding
AU2001293855A1 (en) Vectors for molecule delivery to CD11b expressing cells
US7807377B2 (en) Method of isolating antigen-specific T cells employing artificial antigen presenting cells
Sanderson et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant
US20090324622A1 (en) Antibody vaccine conjugates and uses therefor
HU227508B1 (en) Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease
WO2009014835A9 (en) Modified toxins
JP4024298B2 (ja) 治療薬および自己免疫疾患
JP2003519668A (ja) 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
JPH11513025A (ja) アレルゲン−ｘｃｄ３２融合タンパク質
EP1594533B1 (en) Antibody vaccine conjugates and uses therefor
Feldmann et al. Macrophage-lymphocyte interactions in immune induction
Carayanniotis et al. Characterization of the adjuvant-free serological response to protein antigens coupled to antibodies specific for class II MHC determinants
US7063844B2 (en) Presentation of hydrophobic antigens to T-cells by CD1 molecules
WO2003006055A2 (en) Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
AU2007203473B2 (en) Vectors for Molecule Delivery to CD11b Expressing Cells
HK1057989B (en) Vectors for molecule delivery to cd11b expressing cells
Sant Overview of T-cell recognition: making pathogens visible to the immune system
Atif et al. Sperm membrane lipid liposomes can evoke an effective immune response against encapsulated antigen in BALB/c mice
AU2002311499A1 (en) Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its B subunit
MXPA00009626A (en) Immune response modulator alpha-2 macroglobulin complex

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110719

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120619